HTG Molecular Diagnostics to Present at Canaccord Genuity Growth Conference
HTG Molecular Diagnostics, Inc.
Aug. 01, 2018
TUCSON, Ariz., Aug. 01, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced TJ Johnson, Chief Executive Officer of HTG will present at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 9, 2018 at 10:30 a.m. Eastern Time.
About HTG:HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:Ashley R. RobinsonLifeSci Advisors, LLC617-535-7742 email@example.com
TJ JohnsonChief Executive OfficerHTG Molecular Diagnostics firstname.lastname@example.org